The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIX.e

Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)

Publications

Lam B, Yuile A, Fernando SL

Propylthiouracil-induced vasculitis in carbimazole-refractory Graves disease.

The Medical journal of Australia 2019 06;210;491-491.e1 — 2019 06 — 491-491.e1

Ohwada R, Kato K, Ohmori K, Isozaki O, Hotta M, Ono M, Takano K

A man with interstitial pneumonia due to propylthiouracil.

Internal medicine (Tokyo, Japan) 2003 Oct;42;1026-30 — 2003 Oct — 1026-30

Wada N, Mukai M, Kohno M, Notoya A, Ito T, Yoshioka N

Prevalence of serum anti-myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves' disease treated with propylthiouracil and thiamazole.

Endocrine journal 2002 Jun;49;329-34 — 2002 Jun — 329-34

Noh JY, Asari T, Hamada N, Makino F, Ishikawa N, Abe Y, Ito K, Ito K

Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves' disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations.

Clinical endocrinology 2001 May;54;651-4 — 2001 May — 651-4